Phase 4 N=31 Deprescribing Tamsulosin in Older Men
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Change in Adapted International Prostate Symptom Score (IPSS) — 13.5; 12.1; 14.1; 9.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 SCH: Context-aware Freezing of Gait Mitigation in Real-world Setting
Parkinson Disease
Primary: Number of Freezing of Gait (FoG) Episodes — 3.75; 5.17; 4.0; 3.63 number of freezes
Phase 3 N=343 Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
Ventricular Tachycardia · Atrial Fibrillation
Primary: Amount of Treated Subjects With Freedom of Symptomatic Post-procedural AF or Flutter at 12 and 15 Months Post Procedure and Less Than 1 Min/Day of AF or Flutter on…
Phase 3 N=400 Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
Acute Coronary Syndrome
Primary: Percent Change From Baseline to Day 330 in LDL-C — -45.6; 1.4 Percent change in LDL-C — p=< 0.001
Phase 1 N=6 A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Lungcancer
Primary: Recommended Dose in Milligrams Per Day for Binimetinib. — 30 mg
N/A N=53 TatchSleep as a Tool to Aid in Sleep Apnea Analysis
Sleep Apnea · Sleep Disorder
Primary: Correlation Between Polysomnography (PSG) and Tatch Apnea/Hypopnea Index (AHI) — 0.95 correlation coefficient (r)
Phase 2 N=13 Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
Parkinson Disease · Amyotrophic Lateral Sclerosis
Primary: AMDX-2011P Adverse Events Profile — 0; 1; 3 Treatment Emergent Adverse Events TEAEs
Phase 2 N=314 A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Pneumonia
Primary: Number of Days From the Start of the First Infusion of Study Drug (SFISD) to Recovery — 5; 12; 7.0; 10.0 Days
Phase 2 N=20 Study of Nasal Insulin to Fight Forgetfulness - Device Study
Mild Cognitive Impairment · Cognitive Impairment
Primary: CSF Insulin Levels — 0.14; 0.15 microUnits/mL
Phase 2 N=69 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Oncology · Melanoma · Ovarian Cancer
Primary: Number of Participants Who Experienced AEs or SAEs — 5; 4; 8; 15 Participants
Phase 3 N=397 Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Weekly Itch Severity Score at Week 24 — -6.01; -10.24; -4.81; -7.68 score on a scale — p=0.0005
Phase 3 N=112 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
Acute Myeloid Leukemia (AML)
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) — 3; 4; 4; 1 Participants
N/A N=196 Efficacy of Acupuncture for Lumbar Spinal Stenosis
Lumbar Spinal Stenosis · Intermittent Claudication
Primary: The Change in Modified Roland-Morris Disability Questionnaire (RMDQ) Score From Baseline — -4.3; -3.0 score on a scale
N/A N=50 Text Messaging to Improve Adherence To Repeat Colonoscopy In a Veterans Affairs (VA) Hospital
Colorectal Cancer
Primary: National Annie Colonoscopy Survey Score — 29.56 Score on a scale
Phase 2 N=153 A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
Celiac Disease
Primary: Change in Weekly Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) Symptom Severity Score From Baseline to Week 12 — -0.128; -0.111 score on a scale — p==0.847